BACKGROUND: Approximately 70% of all suicides in patients aged >60 years are attributed to physical illness, with higher rates noted in patients with cancer. The purpose of the current study was to characterize suicide rates among patients with genitourinary cancers and identify factors associated with suicide in this specific cohort. METHODS: Patients with prostate, bladder, kidney, testis, and penile cancer were identified in the Surveillance, Epidemiology, and End Results database (1988-2010). Standardized mortality ratios (SMRs) and 95% confidence intervals (95% CIs) were calculated for each anatomic site. Multivariable logistic regression models generated odds ratios (ORs) for the identification of factors associated with suicide for each malignancy. RESULTS: There were 2268 suicides identified among 1,239,522 individuals with genitourinary malignancies observed for 7,307,377 person-years. The SMRs for patients with cancer were 1.37 for prostate cancer (95% CI, 0.99-1.86), 2.71 for bladder cancer (95% CI, 2.02-3.62), 1.86 for kidney cancer (95% CI, 1.32-2.62), 1.23 for testis cancer (95% CI, 0.88-1.73), and 0.95 for penile cancer (95% CI, 0.65-1.35). On multivariable analysis, male sex was found to be associated with odds of suicide among patients with bladder cancer (OR, 6.63) and kidney cancer (OR, 4.98). Increasing age was associated with suicide for patients with prostate, bladder, and testis cancer (OR range, 1.03-1.06). Distant disease was associated with suicide in patients with prostate, bladder, and kidney cancer (OR range, 2.82-5.43). Among patients with prostate, bladder, and kidney cancer, African American patients were less likely to commit suicide compared with white individuals (OR range, 0.26-0.46). CONCLUSIONS: Suicide in patients with genitourinary malignancies poses a public health dilemma, especially among men, the elderly, and those with aggressive disease. Clinicians should be aware of risk factors for suicide in these patients.
BACKGROUND: Approximately 70% of all suicides in patients aged >60 years are attributed to physical illness, with higher rates noted in patients with cancer. The purpose of the current study was to characterize suicide rates among patients with genitourinary cancers and identify factors associated with suicide in this specific cohort. METHODS:Patients with prostate, bladder, kidney, testis, and penile cancer were identified in the Surveillance, Epidemiology, and End Results database (1988-2010). Standardized mortality ratios (SMRs) and 95% confidence intervals (95% CIs) were calculated for each anatomic site. Multivariable logistic regression models generated odds ratios (ORs) for the identification of factors associated with suicide for each malignancy. RESULTS: There were 2268 suicides identified among 1,239,522 individuals with genitourinary malignancies observed for 7,307,377 person-years. The SMRs for patients with cancer were 1.37 for prostate cancer (95% CI, 0.99-1.86), 2.71 for bladder cancer (95% CI, 2.02-3.62), 1.86 for kidney cancer (95% CI, 1.32-2.62), 1.23 for testis cancer (95% CI, 0.88-1.73), and 0.95 for penile cancer (95% CI, 0.65-1.35). On multivariable analysis, male sex was found to be associated with odds of suicide among patients with bladder cancer (OR, 6.63) and kidney cancer (OR, 4.98). Increasing age was associated with suicide for patients with prostate, bladder, and testis cancer (OR range, 1.03-1.06). Distant disease was associated with suicide in patients with prostate, bladder, and kidney cancer (OR range, 2.82-5.43). Among patients with prostate, bladder, and kidney cancer, African American patients were less likely to commit suicide compared with white individuals (OR range, 0.26-0.46). CONCLUSIONS: Suicide in patients with genitourinary malignancies poses a public health dilemma, especially among men, the elderly, and those with aggressive disease. Clinicians should be aware of risk factors for suicide in these patients.
Authors: Greta M Massetti; Kristin M Holland; Shane P D Jack; Kathleen R Ragan; Natasha Buchanan Lunsford Journal: Psychooncology Date: 2018-04-23 Impact factor: 3.894
Authors: Blayne Welk; Eric McArthur; Michael Ordon; Kelly K Anderson; Jade Hayward; Stephanie Dixon Journal: JAMA Intern Med Date: 2017-05-01 Impact factor: 21.873
Authors: Usama Jazzar; Shan Yong; Zachary Klaassen; Jinhai Huo; Byron D Hughes; Edgar Esparza; Hemalkumar B Mehta; Simon P Kim; Douglas S Tyler; Stephen J Freedland; Ashish M Kamat; Dwight V Wolf; Stephen B Williams Journal: Cancer Date: 2018-04-16 Impact factor: 6.860
Authors: Danyon Anderson; Abrahim N Razzak; Matthew McDonald; David Cao; Jamal Hasoon; Omar Viswanath; Alan D Kaye; Ivan Urits Journal: Health Psychol Res Date: 2022-08-20
Authors: Michael Heinrich; Luisa Hofmann; Hansjörg Baurecht; Peter M Kreuzer; Helge Knüttel; Michael F Leitzmann; Corinna Seliger Journal: Nat Med Date: 2022-03-28 Impact factor: 87.241
Authors: Anne R Cotter; Kim Vuong; Linda Mustelin; Yi Yang; Malika Rakhmankulova; Colleen J Barclay; Russell P Harris Journal: BMJ Open Date: 2017-12-12 Impact factor: 2.692